ArticleMaterials today. Bio2025
Thermosensitive polygalacturonic acid glycoprotein hydrogel encapsulating bionic shikonin nanoparticles for the treatment of psoriasis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in immunocompetent human skin-on-chip models: Construction strategies and biomedical applications.Bioactive materials · 2026Review
- Shikonin-Loaded Nanoparticles Ameliorate DEHP-Exacerbated Psoriasis Skin Injury via Targeted Inhibition of the p38 MAPK Signaling Pathway.International journal of molecular sciences · 2026Article
- Berberine-Mangiferin Self-Assembled Carrier-Free Hydrogel Suppresses NETosis for Augmented Psoriasis Treatment.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is histopathologically characterized by hyperproliferation of keratinocytes, loss of the granular layer, and elongation and thickening of the rete ridges in the epidermis. The thickening of the stratum corneum in psoriatic skin poses a significant barrier to effective drug delivery, as many therapeutic agents with poor solubility, limited release, and side effects struggle to penetrate the skin and achieve prolonged retention, thereby limiting their therapeutic efficacy. To address these challenges, we developed a non-invasive transdermal delivery system. In this system, biomimetic shikonin nanoparticles (CNC) were modified with citric acid and combined with a deep eutectic solvent (DES) composed of L-lysine (L-Lys) and citric acid (CA), forming a CCNCD complex that significantly enhanced the transdermal permeability of CNC. The CCNCD complex was then loaded into a thermosensitive composite hydrogel composed of polygalacturonic acid (PGA)-grafted bovine serum albumin (BSA) and the thermosensitive material F-127 (FPB-CCNCD). This hydrogel exhibited sol-gel transition at body temperature, enabling uniform application on psoriatic skin and prolonging the retention time of CCNCD. The FPB-CCNCD system demonstrated high drug loading capacity, uniform particle size distribution, sustained release, excellent adhesion, enhanced skin retention and penetration in psoriatic-like lesions, and effective targeting of keratinocytes. In vitro experiments revealed that CCNC exhibited strong targeting ability, promoted keratinocyte apoptosis, and reduced the expression of inflammatory cytokines (TNF-α, IL-1β, and IL-6). In an imiquimod-induced psoriatic mouse model, FPB-CCNCD significantly alleviated psoriatic symptoms and reduced the expression of inflammatory factors. Therefore, FPB-CCNCD holds great promise for providing new clinical treatment strategies for psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.